SEARCH

SEARCH BY CITATION

References

  • ALLENBY, K.S., BURRIS, J.F. & MROCZEK, W.J. (1991). Pentoxifylline in the treatment of vascular impotence – case reports. Angiology, 42, 418420.
  • ASHMAN, D.F., LIPTON, R., MELICOW, M.M. & PRICE, T.D. (1963). Isolation of adenosine 3′,5′-monophosphate and guanosine 3′,5′-monophosphate from rat urine. Biochem. Biophys. Res. Commun., 11, 330334.
  • BALLARD, S.A., GINGELL, C.J., TANG, K., TURNER, L.A., PRICE, M.E. & NAYLOR, A.M. (1998). Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol., 159, 21642171.
  • BARBER, R., BAILLIE, G.S., BERGMANN, R., SHEPHERD, M.C., SEPPER, R., HOUSLAY, M.D. & HEEKE, G.V. (2004). Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and non smokers. Am. J. Physiol. Lung Cell Mol. Physiol., 287, L332L343.
  • BARNES, P.J., CHUNG, K.F. & PAGE, C.P. (1988). Inflammatory mediators and asthma. Pharmacol. Rev., 40, 4984.
  • BEAVO, J.A. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 75, 725748.
  • BEAVO, J.A., HARDMAN, J.G. & SUTHERLAND, E.W. (1970). Hydrolysis of cyclic guanosine and adenosine 3′,5′-monophosphates by rat and bovine tissues. J. Biol. Chem., 245, 56495655.
  • BOOLELL, M., ALLEN, M.J., BALLARD, S.A., GEPI-ATTEE, S., MUIRHEAD, G.J., NAYLOR, A.M., OSTERLOH, I.H. & GINGELL, C. (1996). Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res., 8, 4752.
  • BROWN, W.M. (2005). Cilomilast GlaxoSmithKline. Curr. Opin. Inves. Drug, 6, 545558.
  • BUTCHER, R.W. & SUTHERLAND, E.W. (1962). Adenosine 3′,5′-phosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine. J. Biol. Chem., 237, 12441250.
  • CHAN, S.C., REIFSNYDER, D., BEAVO, J.A. & HANIFIN, J.M. (1993). Immunochemical characterisation of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J. Allergy Clin. Immunol., 91, 11791188.
  • CORTIJO, J., BOU, J., BELETA, J., CARDELUS, I., LLENAS, J., MORCILLO, E. & GRISTWOOD, R.W. (1993). Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br. J. Pharmacol., 108, 562568.
  • DE BOER, J., PHILPOTT, A.J., VAN AMSTERDAM, R.G., SHAHID, M., ZAAGSMA, J. & NICHOLSON, C.D. (1992). Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol., 106, 10281034.
  • DENT, G., GIEMBYCZ, M.A., RABE, K.F. & BARNES, P.J. (1991). Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by ‘type IV’-selective PDE inhibitors. Br. J. Pharmacol., 103, 13391346.
  • GIEMBYCZ, M.A., CORRIGAN, C.J., SEYBOLD, J., NEWTON, R. & BARNES, P.J. (1996). Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol., 118, 19451958.
  • Glenmark Pharmaceuticals (2005). GRC3886. Report. http://www.glenmarkpharma.com/research/clinical.html.
  • GUAY, D., HAMEL, P., BLOUIN, M., BRIDEAU, C., CHAN, C.C., CHAURET, N., DUCHARME, Y., HUANG, Z., GIRARD, M., JONES, T.R., LALIBERTE, F., MASSON, P., MCAULIFFE, M., PIECHUTA, H., SILVA, J., YOUNG, R.N. & GIRARD, Y. (2002). Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor. Bioorg. Med. Chem. Lett., 12, 14571461.
  • HAMET, P. & COQUIL, J.F. (1978). Cyclic GMP binding and cyclic GMP phosphodiesterase in rat platelets. J. Cyclic. Nucleotide. Res., 4, 281290.
  • HANSEN, G., JIN, S., UMETSU, D.T. & CONTI, M. (2000). Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc. Natl. Acad. Sci. U.S.A., 97, 67516756.
  • HARBINSON, P.L., MACLEOD, D., HAWKSWORTH, R., O'tOOLE, S., SULLIVAN, P.J., HEATH, P., KILFEATHER, S., PAGE, C.P., COSTELLO, J., HOLGATE, S.T. & LEE, T.H. (1997). The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur. Respir. J., 10, 10081014.
  • HIDAKA, H. & ENDO, T. (1984). Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase–basic and potential clinical applications. Adv. Cyclic. Nucleotide. Protein Phosphorylation. Res., 16, 245259.
  • HOUSLAY, M.D. (2001). PDE4 cAMP-specific phosphodiesterases. Prog. Nucleic. Acid Res. Mol. Biol., 69, 249315.
  • HUGHES, B., HOWAT, D., LISLE, H., HOLBROOK, M., JAMES, T., GOZZARD, N., BLEASE, K., HUGHES, P., KINGABY, R., WARRELLOW, G., ALEXANDER, R., HEAD, J., BOYD, E., EATON, M., PERRY, M., WALES, M., SMITH, B., OWENS, R., CATTERALL, C., LUMB, S., RUSSELL, A., ALLEN, R., MERRIMAN, M., BLOXHAM, D. & HIGGS, G. (1996). The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br. J. Pharmacol., 118, 11831191.
  • IGNARRO, L.J., BUSH, P.A., BUGA, G.M., WOOD, K.S., FUKUTO, J.M. & RAJFER, J. (1990). Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Commun., 170, 843850.
  • Inflazyme pharmaceuticals. (2005). HT0712, a selective PDE4 inhibitor. http://www.inflazyme.com/corporate_profile.
  • JIN, S.L. & CONTI, M. (2002). Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc. Natl. Acad. Sci. U.S.A., 99, 76287633.
  • JONES, N.A., LEPORT, M., HOLAND, T., VOS, T., MORGAN, M., FINK, M., PRUNIAUX, M.-P., BERTHELIER, C., O'CONNOR, B.J., BERTRAND, C. & PAGE, C.P. (2005). Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. Pulm. Pharmacol. Therap., in press).
  • LANDELLS, L.J., SZILAGY, C.M., JONES, N.A, BANNER, K.H., ALLEN, J.M., DOHERTY, A., O’CONNOR, B.J., SPINA, D. & PAGE, C.P. (2001). Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Br. J. Pharmacol., 133, 722729.
  • LIPWORTH, B.J. (2005). Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet, 365, 167175.
  • LUGNIER, C. (2005). Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol. Ther, Epub ahead of print.
  • LUGNIER, C., STIERLE, A., BERETZ, A., SCHOEFFTER, P., LEBEC, A., WERMUTH, C.G., CAZENAVE, J.P. & STOCLET, J.C. (1983). Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases relationship to pharmacological activity. Biochem. Biophys. Res. Commun., 113, 954959.
  • MAGGI, M., FILIPPI, S., LEDDA, F., MAGINI, A. & FORTI, G. (2000). Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur. J. Endocrinol., 143, 143154.
  • MANGANIELLO, V.C., TAIRA, M., DEGERMAN, E. & BELFRAGE, P. (1995). Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). Cell Signal., 7, 445455.
  • MULLER, T., ENGELS, P. & FOZARD, J.R. (1996). Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol. Sci., 17, 294298.
  • MURRAY, K.J. (1993). Phosphodiesterase VA inhibitors. Drug News & Perspectives, 6, 150156.
  • NICHOLSON, C.D., CHALLISS, R.A. & SHAHID, M. (1991). Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci., 12, 1927.
  • NIELSON, C.P., VESTAL, R.E., STURM, R.J. & HEASLIP, R. (1990). Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol., 86, 801808.
  • PACKER, M., CARVER, J.R., RODEHEFFER, R.J., IVANHOE, R.J., DIBIANCO, R., ZELDIS, S.M., HENDRIX, G.H., BOMMER, W.J., ELKAYAM, U. & KUKIN, M.L. (1991). Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med., 325, 14681475.
  • RABE, K.F., BATEMAN, E.D., O’DONNELL, D., WITTE, S., BREDENBROKER, D. & BETHKE, T.D. (2005). Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 366, 563571.
  • RAJFER, J., ARONSON, W.J., BUSH, P.A., DOREY, F.J. & IGNARRO, L.J. (1992). Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med., 326, 9094.
  • RAPOPORT, R.M. & MURAD, F. (1983). Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP. J. Cyclic. Nucleotide. Protein Phosphor. Res., 9, 281296.
  • RENAU, T.E. (2004). The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges. Curr. Opin. Investig. Drugs, 5, 3439.
  • ROBICHAUD, A., STAMATIOU, P.B., JIN, S.L., LACHANCE, N., MACDONALD, D., LALIBERTE, F., LIU, S., HUANG, Z., CONTI, M. & CHAN, C.C. (2002). Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor- mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest., 110, 10451052.
  • RUDD, R.M., GELLERT, A.R., STUDDY, P.R. & GEDDES, D.M. (1983). Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948). Br. J. Dis. Chest., 77, 7886.
  • SCOTT, A.I., PERINI, A.F., SHERING, P.A. & WHALLEY, L.J. (1991). In-patient major depression: is rolipram as effective as amitriptyline Eur. J. Clin. Pharmacol., 40, 127129.
  • SHAHID, M. & NICHOLSON, C.D. (1995). The analysis and assay of cyclic nucleotide phosphodiesterase isoenzyme activity. Methods Mol. Biol., 41, 129150.
  • SOUNESS, J.E. & RAO, S. (1997). Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal., 9, 227236.
  • SUTHERLAND, E.W. (1958). Fractionation and characterisation of a cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem., 232, 10771091.
  • TORPHY, T.J. & UNDEM, B.J. (1991). Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax, 46, 512523.
  • TORPHY, T.J., UNDEM, B.J., CIESLINSKI, L.B., LUTTMANN, M.A., REEVES, M.L. & HAY, D.W. (1993). Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J. Pharmacol. Exp. Ther., 265, 12131223.
  • VAN SCHALKWYK, E., STRYDOM, K., WILLIAMS, Z., VENTER, L., LEICHTL, S., SCHMID-WIRLITSCH, C., BREDENBROKER, D. & BARDIN, P.G. (2005). Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J. Allergy Clin. Immunol., 116, 292298.
  • WALLACE, D.A., JOHNSTON, L.A., HUSTON, E., MACMASTER, D., HOUSLAY, T.M., CHEUNG, Y.F., CAMPBELL, L., MILLEN, J.E., SMITH, R.A., GALL, I., KNOWLES, R.G., SULLIVAN, M. & HOUSLAY, M.D. (2005). Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene. Mol. Pharmacol., 67, 19201934.
  • WESTON, M.C., ANDERSON, N. & PEACHELL, P.T. (1997). Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. Br. J. Pharmacol., 121, 287295.